Fig. 1
6-MP dose intensity and genotype of NUDT15 (a), TPMT (b), and ITPA (c). Patients with ALL received maintenance therapy with 50 mg/m2/d 6-MP according to the CCLG -ALL 2008 protocol. 6-MP dose intensity was defined as the ratio between clinician-prescribed 6-MP dose and protocol dose (%) and was captured on a monthly basis for the 6-month duration of the study. P values were estimated using Mann–Whitney or Kruskal–Wallis nonparametric testing for comparison of independent samples as applicable